Along with the gradual and substantial decline in cognitive and behavioral abilities, Ach deficiency in AD patients is linked to abnormal cholinergic system activity that controls and encourages alterations in tau phosphorylation and APP metabolism, which results in neurotoxicity, neuroinflammation, and neuronal death [195,196]. This evidence concerns the gene MAPT and Alzheimer disease.